Shots:

• The approval of RediTrex is done post no. of communications with the FDA and several amendments to the NDA submitted to the FDA in late 2018
• Cumberland to launch two injectable methotrexate product lines within the US targeted to treat active rheumatoid arthritis- juvenile idiopathic arthritis- and severe psoriasis
• RediTrex (methotrexate) Injection is targeted for adult and pediatric patients with rheumatoid arthritis and adults with psoriasis. Additionally- the company has multiple products in a portfolio focusing on hospital acute care and gastroenterology

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Twitter